These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9369972)

  • 21. [Neuroprotective mechanisms of adenosine action on CNS neurons].
    Zalewska-Kaszubska J
    Neurol Neurochir Pol; 2002; 36(2):329-36. PubMed ID: 12046508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Receptor agonists as perspective neuroprotective agents].
    Kulinskiĭ VI
    Vestn Ross Akad Med Nauk; 2000; (9):39-43. PubMed ID: 11055199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A small animal model of focal cerebral ischemia for studying neuroprotective agents.
    Holland JP; Bell BA
    Ann N Y Acad Sci; 1995 Sep; 765():301-2. PubMed ID: 7486618
    [No Abstract]   [Full Text] [Related]  

  • 24. [Studying the neuroprotective effect of the novel glutamic acid derivative neiroglutam on focal cerebral ischemia in rats].
    Tiurenkov IN; Kurkin DV; Bakulin DA; Volotova EV
    Eksp Klin Farmakol; 2014; 77(9):8-12. PubMed ID: 25365863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of adenosine receptors in neuroprotective effect during global cerebral ischemia.
    Kulinsky VI; Minakina LN; Usov LA
    Bull Exp Biol Med; 2001 May; 131(5):454-6. PubMed ID: 11550051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging strategies for the treatment of ischemic brain injury.
    Ginsberg MD
    Res Publ Assoc Res Nerv Ment Dis; 1993; 71():207-37. PubMed ID: 8417467
    [No Abstract]   [Full Text] [Related]  

  • 27. Modulation of ischemia-evoked release of excitatory and inhibitory amino acids by adenosine A1 receptor agonist.
    Goda H; Ooboshi H; Nakane H; Ibayashi S; Sadoshima S; Fujishima M
    Eur J Pharmacol; 1998 Sep; 357(2-3):149-55. PubMed ID: 9797030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenosine and related drugs in brain diseases: present and future in clinical trials.
    Lopes LV; Sebastião AM; Ribeiro JA
    Curr Top Med Chem; 2011; 11(8):1087-101. PubMed ID: 21401493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of adenosine agonists and an antagonist on excitatory transmitter release from the ischemic rabbit hippocampus.
    Martinez-Tica JF; Zornow MH
    Brain Res; 2000 Jul; 872(1-2):110-5. PubMed ID: 10924682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Saturation of neuroprotective effects of adenosine in cortical culture.
    Lobner D
    Neuroreport; 2002 Nov; 13(16):2075-8. PubMed ID: 12438929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection against global ischemia in the rabbit isolated heart 24 hours after transient adenosine A1 receptor activation.
    Baxter GF; Zaman MJ; Kerac M; Yellon DM
    Cardiovasc Drugs Ther; 1997 Mar; 11(1):83-5. PubMed ID: 9140683
    [No Abstract]   [Full Text] [Related]  

  • 32. Stimulation of adenosine A3 receptors in cerebral ischemia. Neuronal death, recovery, or both?
    von Lubitz DK; Ye W; McClellan J; Lin RC
    Ann N Y Acad Sci; 1999; 890():93-106. PubMed ID: 10668416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effects of L-pGlu-(2-propyl)-L-His-L-ProNH2, a newer thyrotropin releasing hormone analog in in vitro and in vivo models of cerebral ischemia.
    Rajput SK; Siddiqui MA; Kumar V; Meena CL; Pant AB; Jain R; Sharma SS
    Peptides; 2011 Jun; 32(6):1225-31. PubMed ID: 21515320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alert to physicians: possible interaction of aggrenox and adenosine.
    Bergmann SR
    J Am Coll Cardiol; 2000 Oct; 36(4):1432. PubMed ID: 11028507
    [No Abstract]   [Full Text] [Related]  

  • 35. Adenosine A(1) receptor: analysis of the potential therapeutic effects obtained by its activation in the central nervous system.
    Dalpiaz A; Manfredini S
    Curr Med Chem; 2002 Nov; 9(21):1923-37. PubMed ID: 12369876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenosine and the nervous system: clinical implications.
    Guieu R; Couraud F; Pouget J; Sampieri F; Bechis G; Rochat H
    Clin Neuropharmacol; 1996 Dec; 19(6):459-74. PubMed ID: 8937786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke.
    Von Lubitz DK; Simpson KL; Lin RC
    Ann N Y Acad Sci; 2001 Jun; 939():85-96. PubMed ID: 11462807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low doses of the selective adenosine A2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia.
    Melani A; Corti F; Cellai L; Vannucchi MG; Pedata F
    Brain Res; 2014 Mar; 1551():59-72. PubMed ID: 24457041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists.
    Jones PA; Smith RA; Stone TW
    Neuroscience; 1998 Jul; 85(1):229-37. PubMed ID: 9607714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia.
    Von Lubitz DK; Lin RC; Melman N; Ji XD; Carter MF; Jacobson KA
    Eur J Pharmacol; 1994 Apr; 256(2):161-7. PubMed ID: 8050467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.